

The Meeting of the Expanded Bangladesh, Bhutan, India, Nepal, Sri Lanka (BBINS) Malaria Drug Resistance Monitoring Network

A Report

New Delhi, India, 28–29 August 2018



REGIONAL OFFICE FOR

**World Health
Organization**

South-East Asia

The Meeting of the Expanded Bangladesh, Bhutan, India, Nepal, Sri Lanka (BBINS) Malaria Drug Resistance Monitoring Network

A Report

New Delhi, India, 28–29 August 2018



REGIONAL OFFICE FOR

**World Health
Organization**

South-East Asia

The Meeting of the Expanded Bangladesh, Bhutan, India, Nepal, Sri Lanka (BBINS) Malaria Drug Resistance Monitoring Network
SEA-MAL-282

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO license (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this license, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the license shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. The Meeting of the Expanded Bangladesh, Bhutan, India, Nepal, Sri Lanka (BBINS) Malaria Drug Resistance Monitoring Network: World Health Organization, Regional Office for South-East Asia; 2018. License: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

	<i>Page</i>
Abbreviations.....	v
Summary	vii
1. Background.....	1
2. Objectives.....	1
3. Proceedings.....	1
3.1 Opening session	1
3.2 Session 1: Updates	3
3.3 Session 2: Country presentations on recent therapeutic efficacy studies/antimalarial drug efficacy surveillance	5
3.4 Session 3: Operational aspects.....	9
3.5 Planning 2019–2020 surveillance of antimalarial drug efficacy in BBINS+: country and BBINS network plans	11
4. Conclusions and recommendations	13
4.1 Conclusions	13
4.2 Recommendations.....	14
5. Closing session	15

Annexes

1. Agenda.....	16
2. List of participants	18
3. Country plans 2019–2020.....	20

Abbreviations

ACD	active case detection
ACPR	adequate clinical and parasitological response
ACT	artemisinin-based combination therapy
AS	artesunate
BBINS	Bangladesh, Bhutan, India, Nepal, Sri Lanka
CDS	communicable diseases department
CQ	chloroquine
DHA	dihydroartemisinin
ECA	external competency assessment
ETF	early treatment failure
GMP	Global Malaria Programme
GMS	Greater Mekong Subregion
GTS	Global Technical Strategy
HANMAT	Horn of Africa Network for Monitoring Antimalarial Treatment
iDES	integrated Drug Efficacy Surveillance
K13	Kelch 13
LCF	late clinical failure
LPF	late parasitological failure
MQ	mefloquine
NMCP	National Malaria Control Programme
NSP	National Strategic Plan
NTG	National Treatment Guidelines
NVBDCP	National Vector Borne Disease Control Programme
PCD	passive case detection
PIP	piperaquine

预览已结束，完整报告链接和二维码

<https://www.yunbaogao.cn/report/index/report?rep>